Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Depression Clear all
Completed Not applicable Interventional

Cognitive Training for Memory Deficits Associated With Electroconvulsive Therapy

NCT01876758
View directory record Official record
Conditions
Memory Deficits, Electroconvulsive Therapy
Interventions
Cognitive Intervention: Memory Training, Comparable general mental stimulation
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Sep 12, 2026, 6:55 AM EDT
Terminated Not applicable Interventional Results available

Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)

NCT01426516
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Genecept Assay
Device
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 12, 2026, 6:55 AM EDT
Recruiting Not applicable Interventional

rTMS to Target Neural Connectivity and Rumination in Treatment-Resistant Depression

NCT06511544
View directory record Official record
Conditions
Depression, Treatment Resistant
Interventions
Transcranial magnetic stimulation
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 12, 2026, 6:55 AM EDT
Active, not recruiting No phase listed Observational

Open Label Optimization Study

NCT05819021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAINT® Neuromodulation System (NMS)
Device
Lead sponsor
Magnus Medical
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Costa Mesa, California • Los Angeles, California • Sunnyvale, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Phase 3 Interventional

Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression

NCT00179244
View directory record Official record
Conditions
Unipolar Depression
Interventions
Rispridone (drug) and Bupropion ER (drug)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 12, 2026, 6:55 AM EDT
Recruiting Phase 3 Interventional

Biomarker-guided rTMS for Treatment Resistant Depression

NCT04041479
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
22 Years to 65 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 12, 2026, 6:55 AM EDT
Withdrawn Phase 4 Interventional

Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment

NCT00178854
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Risperidone
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Placebo Midazolam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression

NCT03027362
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Cognitive behavioral therapy (CBT) and medication, Psychoeducation and medication
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 12, 2026, 6:55 AM EDT
Terminated No phase listed Observational

Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

NCT01598324
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 12, 2026, 6:55 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

PET Biomarkers in Treatment Resistant Depression

NCT01031810
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 12, 2026, 6:55 AM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Not applicable Interventional Results available

Low Field Magnetic Stimulation for Treatment Resistant Depression

NCT01944644
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active Low Field Magnetic Stimulation, Sham Low Field Magnetic Stimulation
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 12, 2026, 6:55 AM EDT
Suspended Not applicable Interventional

Low-Intensity Focused Ultrasound for Treatment-Resistant Depression

NCT06013384
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Low-Intensity Focused Ultrasound Pulsation, Sham Low-Intensity Focused Ultrasound Pulsation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ketamine in Patients With Treatment-resistant Depression

NCT01627782
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Ketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 12, 2026, 6:55 AM EDT
Active, not recruiting Not applicable Interventional

DBS for TRD With the Medtronic Summit RC+S

NCT04106466
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Medtronic Summit RC+S DBS system
Device
Lead sponsor
Helen Mayberg, MD
Other
Eligibility
25 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Not applicable Interventional Results available

Personalized Therapeutic Neuromodulation for Anhedonic Depression

NCT05144789
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Active TBS-DMPFC, Sham TBS-DLPFC or DMPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Phase 4 Interventional

Combination Therapy in Patients With Depression

NCT00485862
View directory record Official record
Conditions
Depressive Symptoms
Interventions
Atomoxetine Hydrochloride, Sertraline, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Ketamine in Adolescents With Treatment-Resistant Depression

NCT02078817
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 12, 2026, 6:55 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression

NCT06480201
View directory record Official record
Conditions
Healthy, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Ketamine, Saline
Drug · Other
Lead sponsor
Texas A&M University
Other
Eligibility
21 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Not applicable Interventional

A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)

NCT01909232
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
Device
Lead sponsor
Cervel Neurotech, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

NCT03283670
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
Nitrous Oxide 25%, Nitrous Oxide 50%, Placebo Gas
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 12, 2026, 6:55 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 12, 2026, 6:55 AM EDT